Vertex Ventures HC has launched its third and largest fund, the $200 million Fund III, which will be deployed to support life sciences and medical technology companies “aiming to drive innovation and improve patient outcomes”.
Vertex Ventures HC (VVHC) has launched its third and largest fund, the $200 million Fund III, which will be deployed to support life sciences and medical technology companies “aiming to drive innovation and improve patient outcomes.”
VVHC is led by managing directors Lori Hu and Christine Brennan, who possess deep combined investing and operational experience, having led numerous investments in companies that have exited through mergers and acquisitions (M&A) or initial public offerings (IPO).
With a focus on the long term, VVHC has an emphasis on improving diversity at the Board and C-suite and to develop teams that are well positioned for success.
VVHC says Fund III will seek investment opportunities in “early-stage companies that demonstrate disruptive technologies, breakthrough research, and a clear path towards developing new medicines for patients.” VVHC’s extensive network of industry experts, entrepreneurs, and researchers will play a pivotal role in supporting portfolio companies, providing access to valuable resources, strategic partnerships, and mentorship.
Fund III will be led by Hu and Brennan, while David Van Meter, who joined VVHC this year as a venture partner, brings significant operating experience in medical technologies as the former CEO of Ivantis, which was acquired by Alcon.
In addition, industry veterans George Golumbeski, PhD, and Faheem Hasnain continue as Venture Advisors, lending decades of deep operational and business development expertise.
